Serologic Response to Hepatitis B Vaccination in HIV-Infected Patients with Isolated Positivity for Antibodies to Hepatitis B Core Antigen
Identifieur interne : 000A36 ( Istex/Corpus ); précédent : 000A35; suivant : 000A37Serologic Response to Hepatitis B Vaccination in HIV-Infected Patients with Isolated Positivity for Antibodies to Hepatitis B Core Antigen
Auteurs : Catherine Chakvetadze ; Firouzé Bani-Sadr ; Catherine Le Pendeven ; François-Xavier Lescure ; Camille Fontaine ; Tatiana Galperine ; Laurence Slama ; Philippe Bonnard ; Philippe Mariot ; Patrick Soussan ; Gilles PialouxSource :
- Clinical Infectious Diseases [ 1058-4838 ] ; 2010-04-15.
Abstract
We assessed the safety and immunogenicity of hepatitis B vaccination among 40 human immunodeficiency virus-infected patients with isolated positivity for antibodies to hepatitis B core antigen. No baseline factors were found to be predictive of an anamnestic response, which occurred in 32.5% of the patients. The overall response rate among patients without an anamnestic response was 74.0% after 3–6 vaccine doses.
Url:
DOI: 10.1086/651422
Links to Exploration step
ISTEX:49EC5AC0381722D3B3721896918805954EF2512FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Serologic Response to Hepatitis B Vaccination in HIV-Infected Patients with Isolated Positivity for Antibodies to Hepatitis B Core Antigen</title><author><name sortKey="Chakvetadze, Catherine" sort="Chakvetadze, Catherine" uniqKey="Chakvetadze C" first="Catherine" last="Chakvetadze">Catherine Chakvetadze</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Bani Sadr, Firouze" sort="Bani Sadr, Firouze" uniqKey="Bani Sadr F" first="Firouzé" last="Bani-Sadr">Firouzé Bani-Sadr</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: firouze.bani-sadr@tnn.ap-hop-paris.fr</mods:affiliation></affiliation></author><author><name sortKey="Le Pendeven, Catherine" sort="Le Pendeven, Catherine" uniqKey="Le Pendeven C" first="Catherine" last="Le Pendeven">Catherine Le Pendeven</name><affiliation><mods:affiliation>Laboratoire de Virologie, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Lescure, Francois Xavier" sort="Lescure, Francois Xavier" uniqKey="Lescure F" first="François-Xavier" last="Lescure">François-Xavier Lescure</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Fontaine, Camille" sort="Fontaine, Camille" uniqKey="Fontaine C" first="Camille" last="Fontaine">Camille Fontaine</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Galperine, Tatiana" sort="Galperine, Tatiana" uniqKey="Galperine T" first="Tatiana" last="Galperine">Tatiana Galperine</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Slama, Laurence" sort="Slama, Laurence" uniqKey="Slama L" first="Laurence" last="Slama">Laurence Slama</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Bonnard, Philippe" sort="Bonnard, Philippe" uniqKey="Bonnard P" first="Philippe" last="Bonnard">Philippe Bonnard</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Mariot, Philippe" sort="Mariot, Philippe" uniqKey="Mariot P" first="Philippe" last="Mariot">Philippe Mariot</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Soussan, Patrick" sort="Soussan, Patrick" uniqKey="Soussan P" first="Patrick" last="Soussan">Patrick Soussan</name><affiliation><mods:affiliation>Laboratoire de Virologie, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Pialoux, Gilles" sort="Pialoux, Gilles" uniqKey="Pialoux G" first="Gilles" last="Pialoux">Gilles Pialoux</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:49EC5AC0381722D3B3721896918805954EF2512F</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1086/651422</idno><idno type="url">https://api.istex.fr/document/49EC5AC0381722D3B3721896918805954EF2512F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A36</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A36</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Serologic Response to Hepatitis B Vaccination in HIV-Infected Patients with Isolated Positivity for Antibodies to Hepatitis B Core Antigen</title><author><name sortKey="Chakvetadze, Catherine" sort="Chakvetadze, Catherine" uniqKey="Chakvetadze C" first="Catherine" last="Chakvetadze">Catherine Chakvetadze</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Bani Sadr, Firouze" sort="Bani Sadr, Firouze" uniqKey="Bani Sadr F" first="Firouzé" last="Bani-Sadr">Firouzé Bani-Sadr</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: firouze.bani-sadr@tnn.ap-hop-paris.fr</mods:affiliation></affiliation></author><author><name sortKey="Le Pendeven, Catherine" sort="Le Pendeven, Catherine" uniqKey="Le Pendeven C" first="Catherine" last="Le Pendeven">Catherine Le Pendeven</name><affiliation><mods:affiliation>Laboratoire de Virologie, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Lescure, Francois Xavier" sort="Lescure, Francois Xavier" uniqKey="Lescure F" first="François-Xavier" last="Lescure">François-Xavier Lescure</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Fontaine, Camille" sort="Fontaine, Camille" uniqKey="Fontaine C" first="Camille" last="Fontaine">Camille Fontaine</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Galperine, Tatiana" sort="Galperine, Tatiana" uniqKey="Galperine T" first="Tatiana" last="Galperine">Tatiana Galperine</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Slama, Laurence" sort="Slama, Laurence" uniqKey="Slama L" first="Laurence" last="Slama">Laurence Slama</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Bonnard, Philippe" sort="Bonnard, Philippe" uniqKey="Bonnard P" first="Philippe" last="Bonnard">Philippe Bonnard</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Mariot, Philippe" sort="Mariot, Philippe" uniqKey="Mariot P" first="Philippe" last="Mariot">Philippe Mariot</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Soussan, Patrick" sort="Soussan, Patrick" uniqKey="Soussan P" first="Patrick" last="Soussan">Patrick Soussan</name><affiliation><mods:affiliation>Laboratoire de Virologie, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Pialoux, Gilles" sort="Pialoux, Gilles" uniqKey="Pialoux G" first="Gilles" last="Pialoux">Gilles Pialoux</name><affiliation><mods:affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Infectious Diseases</title><title level="j" type="abbrev">Clinical Infectious Diseases</title><idno type="ISSN">1058-4838</idno><idno type="eISSN">1537-6591</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published" when="2010-04-15">2010-04-15</date><biblScope unit="volume">50</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1184">1184</biblScope><biblScope unit="page" to="1186">1186</biblScope></imprint><idno type="ISSN">1058-4838</idno></series><idno type="istex">49EC5AC0381722D3B3721896918805954EF2512F</idno><idno type="DOI">10.1086/651422</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1058-4838</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">We assessed the safety and immunogenicity of hepatitis B vaccination among 40 human immunodeficiency virus-infected patients with isolated positivity for antibodies to hepatitis B core antigen. No baseline factors were found to be predictive of an anamnestic response, which occurred in 32.5% of the patients. The overall response rate among patients without an anamnestic response was 74.0% after 3–6 vaccine doses.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>Catherine Chakvetadze</name><affiliations><json:string>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</json:string></affiliations></json:item><json:item><name>Firouzé Bani-Sadr</name><affiliations><json:string>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</json:string><json:string>E-mail: firouze.bani-sadr@tnn.ap-hop-paris.fr</json:string></affiliations></json:item><json:item><name>Catherine Le Pendeven</name><affiliations><json:string>Laboratoire de Virologie, Hôpital Tenon, Paris, France</json:string></affiliations></json:item><json:item><name>François-Xavier Lescure</name><affiliations><json:string>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</json:string></affiliations></json:item><json:item><name>Camille Fontaine</name><affiliations><json:string>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</json:string></affiliations></json:item><json:item><name>Tatiana Galperine</name><affiliations><json:string>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</json:string></affiliations></json:item><json:item><name>Laurence Slama</name><affiliations><json:string>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</json:string></affiliations></json:item><json:item><name>Philippe Bonnard</name><affiliations><json:string>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</json:string></affiliations></json:item><json:item><name>Philippe Mariot</name><affiliations><json:string>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</json:string></affiliations></json:item><json:item><name>Patrick Soussan</name><affiliations><json:string>Laboratoire de Virologie, Hôpital Tenon, Paris, France</json:string></affiliations></json:item><json:item><name>Gilles Pialoux</name><affiliations><json:string>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</json:string></affiliations></json:item></author><language><json:string>unknown</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>We assessed the safety and immunogenicity of hepatitis B vaccination among 40 human immunodeficiency virus-infected patients with isolated positivity for antibodies to hepatitis B core antigen. No baseline factors were found to be predictive of an anamnestic response, which occurred in 32.5% of the patients. The overall response rate among patients without an anamnestic response was 74.0% after 3–6 vaccine doses.</abstract><qualityIndicators><score>5.066</score><pdfVersion>1.4</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>416</abstractCharCount><pdfWordCount>2334</pdfWordCount><pdfCharCount>14467</pdfCharCount><pdfPageCount>3</pdfPageCount><abstractWordCount>61</abstractWordCount></qualityIndicators><title>Serologic Response to Hepatitis B Vaccination in HIV-Infected Patients with Isolated Positivity for Antibodies to Hepatitis B Core Antigen</title><refBibs><json:item><author><json:item><name>L Piroth</name></json:item><json:item><name>ME Lafon</name></json:item><json:item><name>C Binquet</name></json:item></author><host><volume>40</volume><pages><last>839</last><first>835</first></pages><author></author><title>Scand J Infect Dis</title></host><title>Occult hepatitis B in HIV-HCV coinfected patients</title></json:item><json:item><author><json:item><name>AL French</name></json:item><json:item><name>E Operskalski</name></json:item><json:item><name>M Peters</name></json:item></author><host><volume>195</volume><pages><last>1442</last><first>1437</first></pages><author></author><title>J Infect Dis</title></host><title>Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women</title></json:item><json:item><author><json:item><name>D Neau</name></json:item><json:item><name>M Winnock</name></json:item><json:item><name>T Galperine</name></json:item></author><host><volume>5</volume><pages><last>173</last><first>171</first></pages><author></author><title>HIV Med</title></host><title>Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients</title></json:item><json:item><author><json:item><name>RT Gandhi</name></json:item><json:item><name>A Wurcel</name></json:item><json:item><name>H Lee</name></json:item></author><host><volume>191</volume><pages><last>1441</last><first>1435</first></pages><author></author><title>J Infect Dis</title></host><title>Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies</title></json:item><json:item><author><json:item><name>G Quaglio</name></json:item><json:item><name>F Lugoboni</name></json:item><json:item><name>S Vento</name></json:item></author><host><volume>32</volume><pages><last>144</last><first>143</first></pages><author></author><title>Clin Infect Dis</title></host><title>Isolated presence of antibody to hepatitis B core antigen in injection drug users: do they need to be vaccinated?</title></json:item><json:item><author><json:item><name>A Alberti</name></json:item><json:item><name>N Clumeck</name></json:item><json:item><name>S Collins</name></json:item></author><host><volume>42</volume><pages><last>624</last><first>615</first></pages><author></author><title>J Hepatol</title></host><title>Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients</title></json:item><json:item><author><json:item><name>JK Rockstroh</name></json:item><json:item><name>S Bhagani</name></json:item><json:item><name>Y Benhamou</name></json:item></author><host><volume>9</volume><pages><last>88</last><first>82</first></pages><author></author><title>HIV Med</title></host><title>European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults</title></json:item><json:item><author><json:item><name>WO Bocher</name></json:item><json:item><name>S Herzog-Hauff</name></json:item><json:item><name>J Schlaak</name></json:item><json:item><name>zum Buschenfeld KH Meyer</name></json:item><json:item><name>HF Lohr</name></json:item></author><host><volume>29</volume><pages><last>244</last><first>238</first></pages><author></author><title>Hepatology</title></host><title>Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma</title></json:item><json:item><author><json:item><name>D Rey</name></json:item><json:item><name>V Krantz</name></json:item><json:item><name>M Partisani</name></json:item></author><host><volume>18</volume><pages><last>1165</last><first>1161</first></pages><author></author><title>Vaccine</title></host><title>Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients: effects on HIV-1 viral load</title></json:item><json:item><author><json:item><name>BJ McMahon</name></json:item><json:item><name>AJ Parkinson</name></json:item><json:item><name>C Helminiak</name></json:item></author><host><volume>103</volume><pages><last>594</last><first>590</first></pages><author></author><title>Gastroenterology</title></host><title>Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen</title></json:item><json:item><author><json:item><name>AE Silva</name></json:item><json:item><name>BJ McMahon</name></json:item><json:item><name>AJ Parkinson</name></json:item><json:item><name>MH Sjogren</name></json:item><json:item><name>JH Hoofnagle</name></json:item><json:item><name>AM Di Bisceglie</name></json:item></author><host><volume>26</volume><pages><last>897</last><first>895</first></pages><author></author><title>Clin Infect Dis</title></host><title>Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine</title></json:item><json:item><author><json:item><name>M Cruciani</name></json:item><json:item><name>C Mengoli</name></json:item><json:item><name>G Serpelloni</name></json:item></author><host><volume>27</volume><pages><last>22</last><first>17</first></pages><author></author><title>Vaccine</title></host><title>Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients</title></json:item><json:item><author><json:item><name>A Kabir</name></json:item><json:item><name>M Keshvari</name></json:item><json:item><name>AH Kashani</name></json:item><json:item><name>SM Alavian</name></json:item></author><host><volume>4</volume><pages><last>383</last><first>379</first></pages><author></author><title>Hum Vaccin</title></host><title>Predicting response to HBV vaccination in people with positive anti-HBc but negative HBsAg and anti-HBs</title></json:item><json:item><author><json:item><name>AP Winter</name></json:item><json:item><name>EA Follett</name></json:item><json:item><name>J McIntyre</name></json:item><json:item><name>J Stewart</name></json:item><json:item><name>IS Symington</name></json:item></author><host><volume>12</volume><pages><last>772</last><first>771</first></pages><author></author><title>Vaccine</title></host><title>Influence of smoking on immunological responses to hepatitis B vaccine</title></json:item><json:item><author><json:item><name>O Launay</name></json:item><json:item><name>S Grabar</name></json:item><json:item><name>E Gordien</name></json:item></author><host><volume>49</volume><pages><last>275</last><first>272</first></pages><author></author><title>J Acquir Immune Defic Syndr</title></host><title>Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study</title></json:item><json:item><author><json:item><name>AS Rosman</name></json:item><json:item><name>P Basu</name></json:item><json:item><name>K Galvin</name></json:item><json:item><name>CS Lieber</name></json:item></author><host><volume>103</volume><pages><last>222</last><first>217</first></pages><author></author><title>Am J Med</title></host><title>Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial</title></json:item><json:item><author><json:item><name>MR Wallace</name></json:item><json:item><name>CJ Brandt</name></json:item><json:item><name>KC Earhart</name></json:item></author><host><volume>39</volume><pages><last>1213</last><first>1207</first></pages><author></author><title>Clin Infect Dis</title></host><title>Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects</title></json:item><json:item><author><json:item><name>CL Cooper</name></json:item><json:item><name>JB Angel</name></json:item><json:item><name>I Seguin</name></json:item><json:item><name>HL Davis</name></json:item><json:item><name>DW Cameron</name></json:item></author><host><volume>46</volume><pages><last>1314</last><first>1310</first></pages><author></author><title>Clin Infect Dis</title></host><title>CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years</title></json:item></refBibs><genre><json:string>research-article</json:string></genre><host><volume>50</volume><publisherId><json:string>cid</json:string></publisherId><pages><last>1186</last><first>1184</first></pages><issn><json:string>1058-4838</json:string></issn><issue>8</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1537-6591</json:string></eissn><title>Clinical Infectious Diseases</title></host><categories><wos><json:string>science</json:string><json:string>microbiology</json:string><json:string>infectious diseases</json:string><json:string>immunology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>biomedical research</json:string><json:string>microbiology</json:string></scienceMetrix></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1086/651422</json:string></doi><id>49EC5AC0381722D3B3721896918805954EF2512F</id><score>0.30494487</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/49EC5AC0381722D3B3721896918805954EF2512F/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/49EC5AC0381722D3B3721896918805954EF2512F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/49EC5AC0381722D3B3721896918805954EF2512F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Serologic Response to Hepatitis B Vaccination in HIV-Infected Patients with Isolated Positivity for Antibodies to Hepatitis B Core Antigen</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>The University of Chicago Press</publisher><availability><p>© 2010 by the Infectious Diseases Society of America</p></availability><date>2010</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Serologic Response to Hepatitis B Vaccination in HIV-Infected Patients with Isolated Positivity for Antibodies to Hepatitis B Core Antigen</title><author xml:id="author-1"><persName><forename type="first">Catherine</forename><surname>Chakvetadze</surname></persName><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation></author><author xml:id="author-2" corresp="yes"><persName><forename type="first">Firouzé</forename><surname>Bani-Sadr</surname></persName><email>firouze.bani-sadr@tnn.ap-hop-paris.fr</email><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Catherine</forename><surname>Le Pendeven</surname></persName><affiliation>Laboratoire de Virologie, Hôpital Tenon, Paris, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">François-Xavier</forename><surname>Lescure</surname></persName><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation></author><author xml:id="author-5"><persName><forename type="first">Camille</forename><surname>Fontaine</surname></persName><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation></author><author xml:id="author-6"><persName><forename type="first">Tatiana</forename><surname>Galperine</surname></persName><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation></author><author xml:id="author-7"><persName><forename type="first">Laurence</forename><surname>Slama</surname></persName><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation></author><author xml:id="author-8"><persName><forename type="first">Philippe</forename><surname>Bonnard</surname></persName><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation></author><author xml:id="author-9"><persName><forename type="first">Philippe</forename><surname>Mariot</surname></persName><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation></author><author xml:id="author-10"><persName><forename type="first">Patrick</forename><surname>Soussan</surname></persName><affiliation>Laboratoire de Virologie, Hôpital Tenon, Paris, France</affiliation></author><author xml:id="author-11"><persName><forename type="first">Gilles</forename><surname>Pialoux</surname></persName><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation></author></analytic><monogr><title level="j">Clinical Infectious Diseases</title><title level="j" type="abbrev">Clinical Infectious Diseases</title><idno type="pISSN">1058-4838</idno><idno type="eISSN">1537-6591</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published" when="2010-04-15"></date><biblScope unit="volume">50</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1184">1184</biblScope><biblScope unit="page" to="1186">1186</biblScope></imprint></monogr><idno type="istex">49EC5AC0381722D3B3721896918805954EF2512F</idno><idno type="DOI">10.1086/651422</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><abstract><p>We assessed the safety and immunogenicity of hepatitis B vaccination among 40 human immunodeficiency virus-infected patients with isolated positivity for antibodies to hepatitis B core antigen. No baseline factors were found to be predictive of an anamnestic response, which occurred in 32.5% of the patients. The overall response rate among patients without an anamnestic response was 74.0% after 3–6 vaccine doses.</p></abstract></profileDesc><revisionDesc><change when="2010-04-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/49EC5AC0381722D3B3721896918805954EF2512F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">cid</journal-id><journal-id journal-id-type="publisher-id">cid</journal-id><journal-title>Clinical Infectious Diseases</journal-title><abbrev-journal-title>Clinical Infectious Diseases</abbrev-journal-title><issn pub-type="ppub">1058-4838</issn><issn pub-type="epub">1537-6591</issn><publisher><publisher-name>The University of Chicago Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1086/651422</article-id><article-categories><subj-group subj-group-type="heading"><subject>HIV/AIDS</subject><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></subj-group></article-categories><title-group><article-title>Serologic Response to Hepatitis B Vaccination in HIV-Infected Patients with Isolated Positivity for Antibodies to Hepatitis B Core Antigen</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chakvetadze</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bani-Sadr</surname><given-names>Firouzé</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Le Pendeven</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lescure</surname><given-names>François-Xavier</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fontaine</surname><given-names>Camille</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Galperine</surname><given-names>Tatiana</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Slama</surname><given-names>Laurence</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bonnard</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mariot</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Soussan</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pialoux</surname><given-names>Gilles</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label><institution>Service des Maladies Infectieuses, Hôpital Tenon</institution>, <addr-line>Paris, France</addr-line></aff><aff id="aff2"><label>2</label><institution>Laboratoire de Virologie, Hôpital Tenon</institution>, <addr-line>Paris, France</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Reprints or correspondence: Dr Firouzé Bani-Sadr, Service des Maladies Infectieuses et Tropicales, Hôpital Tenon, 4 rue de la Chine, 75 970 Paris Cedex 20, France (<email>firouze.bani-sadr@tnn.ap-hop-paris.fr</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>4</month><year>2010</year></pub-date><volume>50</volume><issue>8</issue><fpage>1184</fpage><lpage>1186</lpage><history><date date-type="received"><day>17</day><month>9</month><year>2009</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2009</year></date></history><copyright-statement>© 2010 by the Infectious Diseases Society of America</copyright-statement><copyright-year>2010</copyright-year><abstract><p><bold>We assessed the safety and immunogenicity of hepatitis B vaccination among 40 human immunodeficiency virus-infected patients with isolated positivity for antibodies to hepatitis B core antigen. No baseline factors were found to be predictive of an anamnestic response, which occurred in 32.5% of the patients. The overall response rate among patients without an anamnestic response was 74.0% after 3–6 vaccine doses.</bold></p></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Serologic Response to Hepatitis B Vaccination in HIV-Infected Patients with Isolated Positivity for Antibodies to Hepatitis B Core Antigen</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Serologic Response to Hepatitis B Vaccination in HIV-Infected Patients with Isolated Positivity for Antibodies to Hepatitis B Core Antigen</title></titleInfo><name type="personal"><namePart type="given">Catherine</namePart><namePart type="family">Chakvetadze</namePart><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart type="given">Firouzé</namePart><namePart type="family">Bani-Sadr</namePart><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation><affiliation>E-mail: firouze.bani-sadr@tnn.ap-hop-paris.fr</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Catherine</namePart><namePart type="family">Le Pendeven</namePart><affiliation>Laboratoire de Virologie, Hôpital Tenon, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">François-Xavier</namePart><namePart type="family">Lescure</namePart><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Camille</namePart><namePart type="family">Fontaine</namePart><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tatiana</namePart><namePart type="family">Galperine</namePart><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laurence</namePart><namePart type="family">Slama</namePart><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Philippe</namePart><namePart type="family">Bonnard</namePart><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Philippe</namePart><namePart type="family">Mariot</namePart><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Patrick</namePart><namePart type="family">Soussan</namePart><affiliation>Laboratoire de Virologie, Hôpital Tenon, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gilles</namePart><namePart type="family">Pialoux</namePart><affiliation>Service des Maladies Infectieuses, Hôpital Tenon, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><originInfo><publisher>The University of Chicago Press</publisher><dateIssued encoding="w3cdtf">2010-04-15</dateIssued><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>We assessed the safety and immunogenicity of hepatitis B vaccination among 40 human immunodeficiency virus-infected patients with isolated positivity for antibodies to hepatitis B core antigen. No baseline factors were found to be predictive of an anamnestic response, which occurred in 32.5% of the patients. The overall response rate among patients without an anamnestic response was 74.0% after 3–6 vaccine doses.</abstract><relatedItem type="host"><titleInfo><title>Clinical Infectious Diseases</title></titleInfo><titleInfo type="abbreviated"><title>Clinical Infectious Diseases</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">1058-4838</identifier><identifier type="eISSN">1537-6591</identifier><identifier type="PublisherID">cid</identifier><identifier type="PublisherID-hwp">cid</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1184</start><end>1186</end></extent></part></relatedItem><identifier type="istex">49EC5AC0381722D3B3721896918805954EF2512F</identifier><identifier type="DOI">10.1086/651422</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2010 by the Infectious Diseases Society of America</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><covers><json:item><extension>tiff</extension><original>true</original><mimetype>image/tiff</mimetype><uri>https://api.istex.fr/document/49EC5AC0381722D3B3721896918805954EF2512F/covers/tiff</uri></json:item><json:item><extension>html</extension><original>true</original><mimetype>text/html</mimetype><uri>https://api.istex.fr/document/49EC5AC0381722D3B3721896918805954EF2512F/covers/html</uri></json:item></covers><annexes><json:item><extension>jpeg</extension><original>true</original><mimetype>image/jpeg</mimetype><uri>https://api.istex.fr/document/49EC5AC0381722D3B3721896918805954EF2512F/annexes/jpeg</uri></json:item><json:item><extension>gif</extension><original>true</original><mimetype>image/gif</mimetype><uri>https://api.istex.fr/document/49EC5AC0381722D3B3721896918805954EF2512F/annexes/gif</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:49EC5AC0381722D3B3721896918805954EF2512F
|texte= Serologic Response to Hepatitis B Vaccination in HIV-Infected Patients with Isolated Positivity for Antibodies to Hepatitis B Core Antigen
}}
| This area was generated with Dilib version V0.6.29. |  |